Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients

Triple-negative breast cancer is characterized by the absence of estrogen and progesterone receptors and human epidermal growth factor receptor 2, and is associated with a poorer outcome than other subtypes of breast cancer. Moreover, there are no accurate prognostic genes or effective therapeutic targets, thereby necessitating continued intensive investigation. This study analyzed the genetic mutation landscape in 70 patients with triple-negative breast cancer by targeted exome sequencing of tumor and matched normal samples. Sequencing showed that more than 50% of these patients had deleterious mutations and homozygous deletions of DNA repair genes, such as ATM, BRCA1, BRCA2, WRN, and CHEK2. These findings suggested that a large number of patients with triple-negative breast cancer have impaired DNA repair function and that therefore a poly ADP-ribose polymerase inhibitor may be an effective drug in the treatment of this disease. Notably, homozygous deletion of three genes, EPHA5, MITF, and ACSL3, was significantly associated with an increased risk of recurrence or distant metastasis in adjuvant chemotherapy-treated patients.

[1]  Michael B. Stadler,et al.  PIK3CAH1047R induces multipotency and multi-lineage mammary tumours , 2015, Nature.

[2]  May Yin Lee,et al.  Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity , 2015, Nature.

[3]  Tatsuhiko Tsunoda,et al.  A combination of targeted enrichment methodologies for whole-exome sequencing reveals novel pathogenic mutations , 2015, Scientific Reports.

[4]  M. Ladanyi,et al.  Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches , 2015, Clinical Cancer Research.

[5]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[6]  H. Sasaki,et al.  Genetic profiling of thymic carcinoma using targeted next-generation sequencing. , 2014, Lung cancer.

[7]  K. Aldape,et al.  Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours , 2014, British Journal of Cancer.

[8]  İ. Çetin,et al.  Triple negative breast cancer. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[9]  B. Hoh,et al.  A novel rare copy number variant of the ABCF1 gene identified among dengue fever patients from Peninsular Malaysia. , 2014, Genetics and molecular research : GMR.

[10]  Y. Oda,et al.  NOTCH4 is a potential therapeutic target for triple-negative breast cancer. , 2014, Anticancer research.

[11]  L. Holmberg,et al.  Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control , 2013, BMC Genomics.

[12]  Seung-Yong Jeong,et al.  Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing , 2013, PloS one.

[13]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[14]  Francisco M. De La Vega,et al.  Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities , 2012, Molecular Cancer Therapeutics.

[15]  P. Boyle,et al.  Triple-negative breast cancer: epidemiological considerations and recommendations. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[17]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[18]  Kimberly Foreman,et al.  Notch-1 and Notch-4 Biomarker Expression in Triple-Negative Breast Cancer , 2012, International journal of surgical pathology.

[19]  K. Reddy,et al.  Triple-negative breast cancers: an updated review on treatment options. , 2011, Current oncology.

[20]  Shu Ichihara,et al.  Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists , 2011, Modern Pathology.

[21]  J. Lee,et al.  Correction: triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival , 2011, BMC Cancer.

[22]  Debra L Winkeljohn.  Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[23]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[24]  Shinya Watanabe,et al.  NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. , 2008, Cancer research.

[25]  L. Forétova,et al.  Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer , 2008, BMC Cancer.

[26]  W. Han,et al.  BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations. , 2007, Cancer letters.

[27]  S. Ahn,et al.  BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer , 2004, Human mutation.

[28]  Yvonne Freeh,et al.  An R and S–PLUS Companion to Applied Regression , 2004 .

[29]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[30]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[31]  Alfred A. Boyd,et al.  Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 , 1996, Nature Genetics.

[32]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .